TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN COPD PATIENTS BY AIRFLOW LIMITATION SEVERITY: POST-HOC ANALYSES OF THE IMPACT STUDY.

Triple therapy with Fluticasone Furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) was compared with FF/VI and UMEC/VI. For the comparison of FF/UMEC/VI versus FF/VI in patients with a baseline FEV1% >=50%, the only significant improvement was FEV1 (0.097L); P<0.05. [Extracted from the article]